KINE 1020 Lecture Notes - Lecture 16: Orlistat, Tachycardia, Flatulence
29 Mar 2016
School
Department
Course
Professor
Document Summary
Orlistat lipase inhibitor: orlistat (xenical) - blocks fat absorption, generally 5-10 lb weight loss. Flatulence: not covered by ohip, but are generally covered by private insurance plans, orlistat (xenical) Sibutrimine (meridia: appetite control pill, generally 5-8% weight loss. Pulled off the market oct 2010: neurotransmitter reuptake inhibitor, reduces the reuptake of serotonin, norepinephrine, and dopamine. Increases the levels of these substances in synaptic clefts. Monoamine oxidase inhibitors (maois) - a class of antidepressant drugs commonly prescribed for the treatment of depression. Can result in primary pulmonary hypertension, a disease that thickens the capillaries in the lungs and makes breathing very difficult. Heart-valve problems can require risky heart surgery, and primary pulmonary hypertension is a devastating disease for which there is no cure. As a result, pondimin and redux were withdrawn from the market on sept. At recommended doses, both redux and fenfluramine cause serotonin, to be released from certain nerve cells.
